Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Interest & Investment Income (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Interest & Investment Income for 6 consecutive years, with $4.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income fell 47.33% year-over-year to $4.4 million, compared with a TTM value of $23.2 million through Sep 2025, down 16.91%, and an annual FY2024 reading of $32.4 million, up 139.58% over the prior year.
  • Interest & Investment Income was $4.4 million for Q3 2025 at Autolus Therapeutics, down from $5.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $9.7 million in Q2 2024 and bottomed at $165000.0 in Q3 2022.
  • Average Interest & Investment Income over 4 years is $5.1 million, with a median of $4.8 million recorded in 2025.
  • The sharpest move saw Interest & Investment Income skyrocketed 2109.7% in 2023, then plummeted 47.33% in 2025.
  • Year by year, Interest & Investment Income stood at $165000.0 in 2022, then soared by 1724.24% to $3.0 million in 2023, then surged by 147.38% to $7.4 million in 2024, then tumbled by 41.15% to $4.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for AUTL at $4.4 million in Q3 2025, $5.2 million in Q2 2025, and $6.1 million in Q1 2025.